Is Spyre Therapeutics (SYRE) Fully Priced Following Its $350 Million Equity Raise?
Spyre Therapeutics (SYRE) has moved into focus after completing a US$350.0 million follow on equity offering at US$85 per share, adding 4,117,648 common shares at a discount to prior trading.
Recent trading shows that momentum in Spyre Therapeutics has cooled in the short term, with the 7 day share price return down 9.2%, the 30 day move lower by 9.1%, and the 90 day share price performance down 18.1%. This is occurring even though the year to date share price return is 164.4% and the 1 year total shareholder return is very large at over 3.5x, pointing to a stock that has already rewarded early holders while more recent weakness reflects investors reassessing risk after the upsized equity raise and higher cash balance.
Scan beyond Spyre Therapeutics and see how other biotechs are reacting to fresh capital raises and trial funding by reviewing the hand picked 20 high quality undiscovered gems.
Spyre Therapeutics now has more cash and a bigger share count after the US$350.0 million offering, so is most of the upside already in the rear view mirror, or is investors’ optimism only partly priced in?
Most Popular Narrative: 33% Undervalued
Analysts following Spyre Therapeutics see a fair value meaningfully above the last close of $80.85, which puts a spotlight on how much of the story is tied to its antibody pipeline and long cash runway rather than current revenue or earnings.
The plan to use co formulated α4β7, TL1A and IL 23 antibodies with extended half life and high concentration formulations for less frequent subcutaneous dosing, if it translates into high uptake among IBD prescribers, could support premium pricing and help net margins over time.
See why 2 investors see Spyre Therapeutics as 33% undervalued.
Result: Fair Value of $120.08 (UNDERVALUED)
Still, the Spyre Therapeutics story could change quickly if TL1A data in newer autoimmune settings underwhelms or if further insider selling weighs on confidence.
Find out about the key risks to this Spyre Therapeutics narrative.
Next Steps
With sentiment around Spyre Therapeutics clearly mixed, you may want to move quickly and weigh both sides of the story by reviewing the 1 key reward and 5 important warning signs in the 1 key reward and 5 important warning signs.
Looking for more investment ideas beyond Spyre Therapeutics?
If Spyre Therapeutics has your attention, do not stop here. Use the Simply Wall St Screener to compare fresh ideas and pressure test your next move.
- Target resilient balance sheets by scanning companies in the list of solid balance sheet and fundamentals (25 results) and see which businesses pair financial strength with room for upside.
- Hunt for potential mispricings using the 29 high quality undervalued stocks and quickly spot stocks where quality and valuation look out of sync.
- Stack your watchlist with differentiated ideas through the 12 elite penny stocks with strong financials before the crowd starts paying attention.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com